Frontiers of Chemical Science and Engineering >
Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy
Received date: 01 Sep 2016
Accepted date: 11 Mar 2017
Published date: 06 Nov 2017
Copyright
Despite limited successes in clinical development, therapeutic cancer vaccines have experienced resurgence in recent years due to an enhanced emphasis upon co-mitigating factors underlying immune response. Specifically, reversing the immune-suppressive effects of the tumor microenvironment, mediated by a variety of cellular and molecular signaling mechanisms, has become fundamental toward enhancing therapeutic efficacy. Therein, our lab has implemented various nano-vaccines based on the lipid-coated calcium phosphate platform for combined immunotherapy, in which antigenic, epitope-associated peptides as well as immune-suppression inhibitors can be co-delivered, often functioning through the same formulation. In probing the mechanism of action of such systems in vitro andin vivo, an improved effect synergy can be elucidated, inspiring future preclinical efforts and hope for clinical success.
Key words: vaccine; nanoparticle; tumor; immunotherapy; microenvironment
Kai Shi , Matthew Haynes , Leaf Huang . Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy[J]. Frontiers of Chemical Science and Engineering, 2017 , 11(4) : 676 -684 . DOI: 10.1007/s11705-017-1640-4
1 |
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews. Cancer, 2012, 12(4): 237–251
|
2 |
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature, 2011, 480(7378): 480–489
|
3 |
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nature Reviews. Cancer, 2012, 12(4): 265–277
|
4 |
Jeanbart L, Swartz M A. Engineering opportunities in cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(47): 14467–14472
|
5 |
Anguille S, Smits E L, Lion E, van Tendeloo V F, Berneman Z N. Clinical use of dendritic cells for cancer therapy. Lancet Oncology, 2014, 15(7): e257–e267
|
6 |
Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I,
|
7 |
Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman W H, Fucikova J, Galon J, Tartour E, Spisek R,
|
8 |
Lesterhuis W J, de Vries I J, Adema G J, Punt C J. Dendritic cell-based vaccines in cancer immunotherapy: An update on clinical and immunological results. Annals of Oncology, 2004, 15(Suppl 4): 145–151
|
9 |
Smith J D, Morton L D, Ulery B D. Nanoparticles as synthetic vaccines. Current Opinion in Biotechnology, 2015, 34: 217–224
|
10 |
Yang L, Li W, Kirberger M, Liao W, Ren J. Design of nanomaterial based systems for novel vaccine development. Biomaterials Science, 2016, 4(5): 785–802
|
11 |
Schwendener R A. Liposomes as vaccine delivery systems: A review of the recent advances. Therapeutic Advances in Vaccines, 2014, 2(6): 159–182
|
12 |
Silva J M, Videira M, Gaspar R, Preat V, Florindo H F. Immune system targeting by biodegradable nanoparticles for cancer vaccines. Journal of Controlled Release, 2013, 168(2): 179–199
|
13 |
Quail D F, Joyce J A. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 2013, 19(11): 1423–1437
|
14 |
Motz G T, Coukos G. Deciphering and reversing tumor immune suppression. Immunity, 2013, 39(1): 61–73
|
15 |
Munn D H, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Current Opinion in Immunology, 2016, 39: 1–6
|
16 |
Gajewski T F, Schreiber H, Fu Y X. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology, 2013, 14(10): 1014–1022
|
17 |
Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews. Cancer, 2005, 5(4): 263–274
|
18 |
Rabinovich G A, Gabrilovich D, Sotomayor E M. Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology, 2007, 25(1): 267–296
|
19 |
Shiao S L, Ganesan A P, Rugo H S, Coussens L M. Immune microenvironments in solid tumors: New targets for therapy. Genes & Development, 2011, 25(24): 2559–2572
|
20 |
McAllister S S, Weinberg R A. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nature Cell Biology, 2014, 16(8): 717–727
|
21 |
Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo M J. CD4+CD25+Foxp3+ regulatory T-cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nature Immunology, 2007, 8(12): 1353–1362
|
22 |
Chakraborty N G, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Human Immunology, 2004, 65(8): 794–802
|
23 |
Huang Y H, Zozulya A L, Weidenfeller C, Schwab N, Wiendl H. T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. Journal of Leukocyte Biology, 2009, 86(2): 273–281
|
24 |
Huang B, Pan P Y, Li Q, Sato A I, Levy D E, Bromberg J, Divino C M, Chen S H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell energy in tumor-bearing host. Cancer Research, 2006, 66(2): 1123–1131
|
25 |
Zea A H, Rodriguez P C, Atkins M B, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A,
|
26 |
Gabrilovich D I, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews. Immunology, 2009, 9(3): 162–174
|
27 |
Wu A A, Drake V, Huang H S, Chiu S, Zheng L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T-cells. OncoImmunology, 2015, 4(7): e1016700
|
28 |
Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. Journal of Immunology (Baltimore, Md.: 1950), 1997, 159(2): 770–776
|
29 |
Peng Y, Laouar Y, Li M O, Green E A, Flavell R A. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T-cells responsible for protection against diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(13): 4572–4577
|
30 |
Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Research, 2006, 66(11): 5527–5536
|
31 |
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, van den Eynde B J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine, 2003, 9(10): 1269–1274
|
32 |
Munn D H, Sharma M D, Lee J R, Jhaver K G, Johnson T S, Keskin D B, Marshall B, Chandler P, Antonia S J, Burgess R,
|
33 |
Rohrig U F, Majjigapu S R, Vogel P, Zoete V, Michielin O. Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Journal of Medicinal Chemistry, 2015, 58(24): 9421–9437
|
34 |
Saito T, Yokosuka T, Hashimoto-Tane A. Dynamic regulation of T-cell activation and co-stimulation through TCR-microclusters. FEBS Letters, 2010, 584(24): 4865–4871
|
35 |
Walker L S, Sansom D M. Confusing signals: Recent progress in CTLA-4 biology. Trends in Immunology, 2015, 36(2): 63–70
|
36 |
Dong H, Strome S E, Salomao D R, Tamura H, Hirano F, Flies D B, Roche P C, Lu J, Zhu G, Tamada K,
|
37 |
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine, 1999, 5(12): 1365–1369
|
38 |
Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. Journal of Molecular Medicine, 2003, 81(5): 281–287
|
39 |
Curiel T J, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson K L, Daniel B, Zimmermann M C,
|
40 |
Webster R M. The immune checkpoint inhibitors: Where are we now? Nature Reviews. Drug Discovery, 2014, 13(12): 883–884
|
41 |
Juliano R L, Carver K. Cellular uptake and intracellular trafficking of oligonucleotides. Advanced Drug Delivery Reviews, 2015, 87: 35–45
|
42 |
Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Review of Vaccines, 2015, 14(2): 221–234
|
43 |
Marceau F, Bawolak M T, Lodge R, Bouthillier J, Gagne-Henley A, Gaudreault R C, Morissette G. Cation trapping by cellular acidic compartments: Beyond the concept of lysosomotropic drugs. Toxicology and Applied Pharmacology, 2012, 259(1): 1–12
|
44 |
Mansourian M, Badiee A, Jalali S A, Shariat S, Yazdani M, Amin M, Jaafari M R. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunology Letters, 2014, 162(1): 87–93
|
45 |
Horiuchi Y, Takagi A, Uchida T, Akatsuka T. Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo. Oncology Reports, 2015, 34(6): 2827–2836
|
46 |
Kojima N, Biao L, Nakayama T, Ishii M, Ikehara Y, Tsujimura K. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. Journal of Controlled Release, 2008, 129(1): 26–32
|
47 |
Ikehara Y, Shiuchi N, Kabata-Ikehara S, Nakanishi H, Yokoyama N, Takagi H, Nagata T, Koide Y, Kuzushima K, Takahashi T,
|
48 |
Choi D H, Kim K S, Yang S H, Chung D H, Song B, Sprent J, Cho J H, Sung Y C. Dendritic cell internalization of alpha-galactosylceramide from CD8 T-cells induces potent antitumor CD8 T-cell responses. Cancer Research, 2011, 71(24): 7442–7451
|
49 |
Neumann S, Young K, Compton B, Anderson R, Painter G, Hook S. Synthetic TRP2 long-peptide and alpha-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression. Vaccine, 2015, 33(43): 5838–5844
|
50 |
Xu Z, Ramishetti S, Tseng Y C, Guo S, Wang Y, Huang L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. Journal of Controlled Release, 2013, 172(1): 259–265
|
51 |
Xu Z, Wang Y, Zhang L, Huang L. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano, 2014, 8(4): 3636–3645
|
52 |
Vangasseri D P, Han S J, Huang L. Lipid-protamine-DNA-mediated antigen delivery. Current Drug Delivery, 2005, 2(4): 401–406
|
53 |
Dileo J, Banerjee R, Whitmore M, Nayak J V, Falo L D Jr, Huang L. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Molecular Therapy, 2003, 7(5): 640–648
|
54 |
Miura N, Shaheen S M, Akita H, Nakamura T, Harashima H. A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant. Nucleic Acids Research, 2015, 43(3): 1317–1331
|
55 |
Shaheen S M, Akita H, Nakamura T, Takayama S, Futaki S, Yamashita A, Katoono R, Yui N, Harashima H. KALA-modified multi-layered nanoparticles as gene carriers for MHC class-I mediated antigen presentation for a DNA vaccine. Biomaterials, 2011, 32(26): 6342–6350
|
56 |
Zhuang X, Wu T, Zhao Y, Hu X, Bao Y, Guo Y, Song Q, Li G, Tan S, Zhang Z. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma. Journal of Controlled Release, 2016, 228: 26–37
|
57 |
Ruiz-de-Angulo A, Zabaleta A, Gomez-Vallejo V, Llop J, Mareque-Rivas J C. Microdosed Lipid-coated (67)Ga-magnetite enhances antigen-specific immunity by image tracked delivery of antigen and CpG to lymph nodes. ACS Nano, 2016, 10(1): 1602–1618
|
58 |
Zhang Z, Tongchusak S, Mizukami Y, Kang Y J, Ioji T, Touma M, Reinhold B, Keskin D B, Reinherz E L, Sasada T. Induction of anti-tumor cytotoxic T-cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials, 2011, 32(14): 3666–3678
|
59 |
Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, Bouvet M, Kruse C, Grotjahn D, Ichim T,
|
60 |
Heo M B, Lim Y T. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials, 2014, 35(1): 590–600
|
61 |
Guo Y, Wang D, Song Q, Wu T, Zhuang X, Bao Y, Kong M, Qi Y, Tan S, Zhang Z. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano, 2015, 9(7): 6918–6933
|
62 |
Silva J M, Zupancic E, Vandermeulen G, Oliveira V G, Salgado A, Videira M, Gaspar M, Graca L, Preat V, Florindo H F. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. Journal of Controlled Release, 2015, 198: 91–103
|
63 |
Cui L, Osada K, Imaizumi A, Kataoka K, Nakano K. Feasibility of a subcutaneously administered block/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model. Journal of Controlled Release, 2015, 206: 220–231
|
64 |
Furugaki K, Cui L, Kunisawa Y, Osada K, Shinkai K, Tanaka M, Kataoka K, Nakano K. Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models. PLoS One, 2014, 9(7): e101854
|
65 |
Luo Z, Wang C, Yi H, Li P, Pan H, Liu L, Cai L, Ma Y. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo. Biomaterials, 2015, 38: 50–60
|
66 |
Luo Z, Li P, Deng J, Gao N, Zhang Y, Pan H, Liu L, Wang C, Cai L, Ma Y. Cationic polypeptide micelle-based antigen delivery system: A simple and robust adjuvant to improve vaccine efficacy. Journal of Controlled Release, 2013, 170(2): 259–267
|
67 |
Li J, Chen Y C, Tseng Y C, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. Journal of Controlled Release, 2010, 142(3): 416–421
|
68 |
Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. Journal of Controlled Release, 2012, 158(1): 108–114
|
69 |
Haynes M T, Huang L. Lipid-coated calcium phosphate nanoparticles for nonviral gene therapy. Advances in Genetics Incorporating Molecular Genetic Medicine, 2014, 88: 205–229
|
70 |
Curran M A, Montalvo W, Yagita H, Allison J P. PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(9): 4275–4280
|
71 |
Fridlender Z G, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti M C, Wang L C, Heitjan D, Snyder L A, et al. CCL2 blockade augments cancer immunotherapy. Cancer Research, 2010, 70(1): 109–118
|
72 |
Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research, 2003, 63(15): 4441–4449
|
73 |
Zeng J, Cai S, Yi Y, He Y, Wang Z, Jiang G, Li X, Du J. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan. Cancer Research, 2009, 69(9): 3963–3970
|
74 |
Liao D, Liu Z, Wrasidlo W J, Luo Y, Nguyen G, Chen T, Xiang R, Reisfeld R A. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Research, 2011, 71(17): 5688–5696
|
75 |
Chono S, Li S D, Conwell C C, Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. Journal of Controlled Release, 2008, 131(1): 64–69
|
76 |
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nature Reviews. Immunology, 2007, 7(1): 41–51
|
77 |
Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nature Reviews. Cancer, 2014, 14(11): 736–746
|
78 |
Furtek S L, Backos D S, Matheson C J, Reigan P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chemical Biology, 2016, 11(2): 308–318
|
79 |
Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Research, 2008, 18(2): 254–267
|
80 |
Singh M, Ramos I, Asafu-Adjei D, Quispe-Tintaya W, Chandra D, Jahangir A, Zang X, Aggarwal B B, Gravekamp C. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Medicine, 2013, 2(4): 571–582
|
81 |
Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunology and Cell Biology, 2008, 86(6): 506–514
|
82 |
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews. Cancer, 2009, 9(11): 798–809
|
83 |
Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen Y, Xiang G, Huang L. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Molecular Therapy, 2016, 24(2): 364–374
|
84 |
Nagaraj S, Youn J I, Weber H, Iclozan C, Lu L, Cotter M J, Meyer C, Becerra C R, Fishman M, Antonia S,
|
85 |
Zhao Y, Huo M, Xu Z, Wang Y, Huang L. Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma. Biomaterials, 2015, 68: 54–66
|
/
〈 | 〉 |